Kornimate/medical-research-clean huggingface dataset:
voice feminisation in transgender women

Conditions: Speech Therapy; Transgender Women; Gender Dysphoria

Summary: the voice is a reflection of our identity. in the case of transgender women, there may be a gap between perceived male voice and female appearance. indeed, hormonal treatment in transgender women has no effect on the voice quality. this gap can have negative consequences on everyday life in banal situations such as telephonic contact leading to limited use of phone calls and social isolation. differences between female and male voices seem to be socially determined and do not depend directly on sexual dimorphism of the phonatory organs. speech therapy might thus be indicated as a vocal support for transgender women. only few studies have examined the impact of perceived voice on the quality of life of transgender women.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * follow-up in the department of endocrinology, diabetology and nutrition of the university hospital of nancy * gender dysphoria according to the icd 11 * voluntary, informed consent to participate in research * compulsory affiliation to the social security system exclusion criteria: -refusal or incapacity to be involved in the study
two different surgical techniques for the treatment of multiple gingival recessions with porcine collagen matrix

Conditions: Gingival Recession; Xenograft Model; Gingival Recession, Generalized

Summary: the gold standard for gingival recession treatment is the coronal repositioning of the flap associated with the subepithelial connective tissue graft. the porcine collagen matrix (pcr) has been used as a substitute for subepithelial connective tissue graft in periodontal plastic surgery and has achieved similar results. the pcr use has the advantage of avoiding possible pre and postoperative complications , as well as overcome the limitations presented by autograft . the different surgical techniques used for root coverage seek predictability and success . for this, besides the type of incision placements flap and graft are the most important because the healing benefits and outcome . the aim of this study is to compare two surgical techniques for root coverage and evaluate which one provides better clinical outcomes and less morbidity . 20 adults , nonsmoking patients , showing multiple bilateral gingival recessions , class i or ii miller located in canine, first and second premolars are selected. both techniques use the pcr as a graft . however, in one quadrant partial flap will be held together with relaxing incisions through an intrasulcular incision, pcr will be positioned 1 mm apical to the cementoenamel junction (cej) and the flap will be positioned 1 mm coronal cej. in the opposite quadrant periosteal envelope that does not use relaxing incisions, avoiding any scars, will be performed with the pcr. the clinical parameters (gingival recession height and width, keratinized tissue thickness and width) will be evaluated 2 weeks after basic periodontal therapy and after 6 and 12 months to surgical procedures..


Eligibility criteria:
inclusion criteria: -bilateral multiple gingival recession type miller class i or ii with at least one tooth with 3 mm of gingival recession height exclusion criteria: * diabetics * pregnant women * chronic use of medication * periodontitis * smokers

Keywords: gingival recession porcine collagen matrix multiple gingival recessions tunnel technique
combination of diclofenac potassium and propolis in the therapy of oral aphthosis

Conditions: Oral Mucositis; ORAS; Oral Infection; Oral Ulcer

Summary: the combination of diclofenac and propolis could enhance the healing of recurrent aphthous ulcers, instantly relieve symptoms, improve the quality of life, and present a de novo and cost-effective regime help in oral ulcer treatment. this study aimed to evaluate the influence of diclofenac and propolis combination as a gel in the treatment of recurrent oral ulceration


Eligibility criteria:
inclusion criteria: * patients have an oral mucosal ulcer exclusion criteria: * patients allergic to any component of the diclofenac formulation and other nsaids

Keywords: diclofenac oral disease oral aphthosis propolis
effect of orange juice on glycemic response

Conditions: Effect of Food on Postprandial Hyperglycemia

Summary: orange juice naturally contains high concentrations of hesperidin, which affects glucose absorption in in vitro experiments. this study is to test if hesperidin and other components of orange juice (not other sugars or organic acids) affect the post-prandial blood glucose concentration derived from sugars already present in the orange juice.

healthy volunteers will consume orange juice with added water or food-grade hesperidin.

Eligibility criteria:
inclusion criteria: * fasting blood glucose below 5.9 mm exclusion criteria: * fasting glucose above 6 mm pregnant
slow opioid tapering pilot study of patients using chronic opioid therapy

Conditions: Chronic Pain; Opioid Use

Summary: the purpose of this study is to find out if patients who have been taking a stable dose of opioids for chronic pain would experience any worsening pain, quality of life and functioning, as well as symptoms of depression and anxiety if their opioid medications are gradually and very slowly reduced.


Eligibility criteria:
inclusion criteria: * ability to provide consent. * ability to participate in all aspects of this study. * using tablet or capsule form of one or two of the designated opioid preparations daily (at least 95% of days) during the previous 6 months, anticipated long term use and no active plans for tapering. specific opioid preparations designated for inclusion will be based on the frequency of use by patients on the chronic opioid registry as well as tablet or capsule characteristics which allow encapsulation by the research pharmacy. participants who have been prescribed the following oral opioids will be recruited into the study: tramadol 50mg tablet or capsule; hydrocodone-acetaminophen (apap) 5mg-325mg tablet or capsule; hydrocodone-apap 7.5mg-325mg tablet or capsule; hydrocodone-apap 10mg-325mg tablet or capsule; oxycodone 5mg tablet or capsule; oxycodone 10mg tablet or capsule; oxycodone-apap 5mg-325mg tablet or capsule; oxycodone 10mg-325mg tablet or capsule; morphine sulfate extended release 15mg tablet or capsule; morphine sulfate extended release 30mg tablet or capsule; morphine sulfate immediate release 15mg tablet or capsule; morphine sulfate immediate release 30mg tablet or capsule. * primary care provider prescribing chronic opioid therapy within mchs nw wi and in agreement with patient participation. * average daily morphine milligram equivalent (mme) dose at enrollment equal to or less than 90. exclusion criteria: * daily or intermittent use of transdermal, liquid, intravenous or intramuscular forms of opioid during the last 6 months. * use of methadone or buprenorphine. * use of an opioid containing preparation with three or more active ingredients. * active cancer treatment, other than non-melanoma dermatological cancers. this includes patients either currently receiving or planning to receive any type of cancer treatment other than hormonal therapy. * active or planned pregnancy. * cot being prescribed for indications other than chronic non-cancer pain (i.e., restless leg syndrome). * enrollment in hospice care. * active suicidal planning or intent as reported on phq9. * acquisition of controlled medications from clinicians other than pcp or associated clinicians in the previous 6 months as noted in the prescription drug monitoring program. * use of opioids and/or benzodiazepines other than those prescribed by pcp or associated clinicians, or the use of illicit substances other than thc, as found in urine drug testing within the previous 6 months. * known history of any condition or factor judged by the investigator to preclude participation in the study or which might hinder adherence.

Keywords: chronic opioid therapy
the effect of zinc, β-carotene, and vitamin d3 in preterm delivery through placental myd88, trif, nfkb, and il-1β

Conditions: PreTerm Birth

Summary: this study is a controlled trial which compares the effect of zinc, beta-carotene, and vitamin d3 supplementation in pregnant women which has preterm birth. the measured outcome is zinc, vitamin a, and 25(oh)d level in serum and placenta, myd88, trif, nfκb, and il-1β levels in placenta.

the research will be held in cipto mangunkusumo general and budi kemuliaan hospital. each participant of each group will be given the medication of preterm birth hospital protocol, which includes nifedipine 4x10 mg as tocolytic agent, dexamethasone 2x6 mg intravenous for 2 days which aims to support lung maturation, and antibiotic. then, the blood sample is obtained for zinc, vitamin a and 25(oh)d levels examination. subjects will be divided into 2 groups which are group whose given the oral zinc 50 mg/day, oral beta-carotene 25,000 iu and oral vitamin d3 50,000 iu/week supplementation, and group who is not given the intervention. each participant will be observed until delivery. after delivery, level of zinc, vitamin a, and 25(oh)d in serum and placenta will be measured, as well as level of myd88, trif, nfκb, and il-1β in placenta.

Eligibility criteria:
inclusion criteria: * pregnant women who has preterm birth in 26-36 weeks gestational age exclusion criteria: * multiple pregnancy * drug allergy * intra uterine growth retardation (iugr) is detected * congenital malformation in fetus was found * preterm premature rupture of membrane (pprom) * maternal complication such as gestational hypertension, preeclampsia, gestational diabetes mellitus, heart disease, infection, and autoimmune disease
trial of vacuum assisted closure® therapy in amputation wounds of the diabetic foot

Conditions: Diabetic Foot

Summary: the purpose of this study is to compare the effectiveness of vacuum assisted closure® (v.a.c.®) therapy to moist wound therapy of amputation wounds of the diabetic foot. the primary objective is to determine the effect of v.a.c.® therapy on the incidence of complete wound closure. secondary objectives include evaluating the acceleration of wound closure, facilitation of surgical closure, incidence of foot salvage, and incidence of wound complications.


Eligibility criteria:
inclusion criteria: 1. presence of a diabetic foot amputation wound up to the transmetatarsal region of the foot 2. evidence of adequate perfusion by one of the following on the affected extremity, (within the past 60 days): * dorsum transcutaneous oxygen test (tcpo2) with results of ≥30 mmhg, or * ankle brachial index (abis) with results of ≥0.7 and ≤1.2 and toe pressures with results of ≥30 mmhg, or * doppler arterial waveforms, which are triphasic or biphasic at the ankle in the affected leg. 3. age ≥ 18 years of age 4. hba1c ≤ 12% (collected within the last 90 days.) 5. evidence of adequate nutrition by one of the following: * lab results reflecting pre-albumin ≥16 mg/dl and albumin level is ≥3 g/dl (during the seven days prior to the study period), or * a nutritional consult will be done and with appropriate supplementation started. proper documentation on (case report forms)crfs is needed. exclusion criteria: 1. patients with recognized active charcot abnormalities of the foot, as evidence by clinical symptoms that interfere with either randomized treatment group 2. wounds resulting from electrical, chemical, or radiation burns, or venous insufficiency 3. untreated infection or cellulitis at site of target wound 4. presence of untreated osteomyelitis 5. collagen vascular disease 6. malignancy in the wound 7. presence of necrotic tissue in the wound 8. uncontrolled hyperglycemia 9. concomitant medications that include (washout period of 30 days for corticosteroids, immunosuppressive medications, or chemotherapy) 10. prior v.a.c.® therapy within 30 days. 11. current or prior normothermic (warm-up®) or hyperbaric oxygen (hbo) therapy within 30 days. 12. current or prior treatment with recombinant or autologous growth factor products within the past 30 days. (examples: regranex or procuren) 13. current or prior treatment with skin or dermal substitutes and dressings (examples: apligraf, dermagraft, or integra) with living cells capable of producing growth factors (example: oasis) within the past 30 days.

Keywords: wound closure foot salvage accelerated healing amputation wounds of the diabetic foot
evaluation of canadvice+®m-health system to support breast cancer patients receiving capecitabine

Conditions: Metastatic Breast Cancer

Summary: this feasibility study will be conducted in order to provide proof of concept for the canadvice+® system comprising a smart phone app and a healthcare organization server side application based on web 2 technologies. the main objective of this project is to optimise pharmaceutical counselling services by providing drug related information, in a digital format, to patients with metastatic breast cancer receiving capecitabine.


Eligibility criteria:
inclusion criteria: * patients diagnosed with metastatic breast cancer * commencing first cycle of capecitabine * familiar with and own an android smartphone * willing to participate exclusion criteria: * patients \<18 years * patients taking part in any other trial containing capecitabine * chemotherapy-naïve patients
cryptic bacteria of the thyroid tissue as a possible cause of the pathology of this organ

Conditions: Bacteria Infection Mechanism

Summary: the presence of cryptic microbes has been widely documented in animal healthy deep tissues. the thyroid gland is an organ specifically exposed to the microbial environment due to its close location to the mouth microbiome. a number of bacterial phenotypes has been detected in the inflamed thyroid gland. a question raises as to whether bacteria have not already been present in the thyroid gland before the clinical symptoms of goiter became evident. a problem in thyroid surgery, relatively uncommon but difficult for control, is prolonged thyroidectomy wound healing with skin flap, gland bed inflammation and fibrosis. the causative bacteria may belong to the strains persistently present in the thyroid gland parenchyma. our objective is to answer questions: a) do the goiter tissue structures contain bacteria, b) if so, which bacterial phenotypes can be identified, c) what are the genetic similarities of the thyroid and periodontal bacterial strains. studies are carried out in patients with non-toxic multinodular goiter, toxic multinodular goiter, graves' disease, single adenoma, hashimoto's disease, thyroid cancer and recurrent thyroid disease. tissue harvested during surgery is dissected immediately after thyroidectomy into fragments of parenchyma, arteries, veins and lymph nodes and cultured on columbia blood agar base for up to 3 weeks. in this method bacteria present in the tissue grow in their natural environment, slowly proliferate and then form the on-plate colonies. it enables detection of even single bacteria usually difficult to be identified in planktonic media. identification of the isolated bacteria is performed. their dna patterns are also compared.


Eligibility criteria:
inclusion criteria: * thyroid disease requiring surgery exclusion criteria: * acute or chronic infection at remote sites * treated with antibiotics over the last 3 months
liraglutide as add-on to insulin in type 1 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 1

Summary: the purpose of this study is to: part 1: to investigate how 12 weeks treatment with liraglutide affects glycemic control in poorly controlled patients and how the treatment affects gastric emptying rate during hypoglycemia. part 2: to investigate how 12 weeks treatment of type 1 diabetic patients with liraglutide affects counterregulatory hormones and cognitive performance during hypoglycemia.


Eligibility criteria:
inclusion criteria: * age: 18-70 years * bmi: 18-28 * hba1c ≥ 8 % * no residual β-cell function (glucagon test with c-peptide \< 60 pm) * caucasian * diagnosed with type 1 diabetes at 5 to 40 years of age (both inclusive). * remission phase must be completed * female participants must use adequate contraception * informed consent exclusion criteria: * overt diabetes complications; creatinin \> 130 µm, proliferative retinopathy, macroalbuminuria. * autonomic neuropathy (rr-variation \</=10 beats/min) and/or orthostatic hypotension (oh). * anemia, hb concentration; female \<7.0 mmol/l, male\<8.0 mmol/l * pregnancy or lactation * epilepsy * use of antiepileptic medication * use of beta blockers * previously apoplexy cerebri. * any use of benzodiazepine within the last month * any use of neuroleptic drugs within the last six months * self-perceived hearing loss * alcohol or drug abuse * allergy to the medication or placebo. * treatment with any medication affecting glucose metabolism. * any disorder which in the investigators opinion could interfere with the safety and results of the trial

Keywords: diabetes mellitus diabetes mellitus, type 1 glucose metabolism disorders metabolic diseases cognitive performance hypoglycemia insulin glucagon-like peptide 1 hypoglycemic agents physiological effects of drugs pharmacologic actions incretins hormones
eeg phase synchrony, sedation and delirium in the cvicu

Conditions: Delirium

Summary: eeg phase synchrony and variability has had limited investigation during transition from coma to wakefulness in response to sedation and analgesia. studying changes in phase synchrony and variability during and after sedative-induced coma is an exciting opportunity to better understand eeg changes during transitions in states of arousal. it is expected that consciousness should be higher in entropy and greater in complexity in the number of configurations of pairwise connections as compared to sedative-induced coma. if sufficiently sensitive, it may be possible to identify states of lower entropy and fewer configurations when patient are aroused but with altered sensorium (e.g. delirium).

aim 1: to quantify eeg phase synchrony changes, both globally and locally by brain region, during emergence from medically induced coma required for performance of a cardiovascular related operation (deep sedation defined as a riker sedation-agitation scale \[sas\] of 1-2). hypothesis: the global r-index will be increased above baseline at multiple frequency bandwidths and the magnitude of r-index will correlate with the sedative dosage (as a crude measure of depth). the rate of fluctuations of the r-index will decrease with deeper sedation. aim 2: to compare the magnitude of the eeg phase synchrony globally and locally in patients emerging from coma; a patient's pre-anesthesia phase will serve as a control. hypothesis: fluctuations in r-index will vary; fluctuations will be greater in awake adults as compared to while comatose or emerging from coma. aim 3: to determine eeg phase synchrony changes in patients with and without delirium during their cvicu stay. hypothesis: lower scores of r-index consistent with increased phase synchrony and lower spatio-temporal variability will be seen while delirious as compared to days when patients are not delirious.

Eligibility criteria:
inclusion criteria: * age 30 - 65 years * scheduled for first-time cabg or single valve replacement exclusion criteria: * previous stroke * severe pre-existing cognitive impairment (tics score \< 24)
capsular contracture after pmrt using prepectoral versus subpectoral implant-based breast reconstruction: preper trial

Conditions: Breast Cancer

Summary: the purpose of this study is to prospectively compare and analyze the incidence of complications in patients undergoing postmastectomy radiation therapy after breast reconstruction with subpectoral and prepectoral placement of implant. investigators hypothesized that immediate acellular dermal matrix-assisted implant-based breast reconstruction with prepectoral implant placement would result in lower risk of capsular contracture after postmastectomy radiation therapy(pmrt) compared with acellular dermal matrix(adm)-assisted implant-based breast reconstruction with subpectoral implant placement.

outline: this is a single center randomized clinical trial. participant recruitment and enrollment will occur at gangnam severance hospital breast cancer center for 4 years, followed by one year of follow up data collection and analysis. arm i (prepectoral): immediate adm-assisted implant-based breast reconstruction with prepectoral implant placement. arm ii (subpectoral): immediate adm-assisted implant-based breast reconstruction with subpectoral implant placement. this clinical study is aimed at patients who have been diagnosed with breast cancer and who have undergone a total mastectomy for the therapeutic indication, and who are planning to undergo implant based reconstruction and postmastectomy radiotherapy. it will be carried out prospectively in a single institution, and the study will be divided into two groups, subpectoral implant and prepectoral implant, according to the reconstruction method. a total of 96 patients or 48 patients per arm will be recruited. randomization will be accomplished using randomly permuted blocks, and randomization will be stratified on the basis of reconstruction method. (tissue expander insertion or direct-to-implant) after completion of study treatment, patients are followed for 1 year for observation of capsular contracture and patient reported outcomes.

Eligibility criteria:
inclusion criteria: 1. age over 19 years old 2. histologically confirmed diagnosis of unilateral breast cancer 3. mastectomy (nipple or skin sparing mastectomy) candidate for therapeutic indication 4. patient undergoing immediate implant based breast reconstruction exclusion criteria: 1. underlying medical condition: for example, (ast or alt \>100u/l, inadequate renal function; egfr \< 30ml/min, congestive heart failure; new york heart association iii-iv) 2. prior history of radiotherapy on the affected side of breast or chest wall before mastectomy 3. history of a known additional malignancy note: participants with melanoma of skin, low grade thyroid cancer are not excluded. 4. not able to provide informed consent (illiterate, foreigners, etc.)

Keywords: breast cancer breast implants
hydromark post-market clinical follow-up study

Conditions: Breast Cancer

Summary: the purpose of this study is to assess the safety and performance of the hydromark breast biopsy site marker manufactured in the devicor medical products, inc. tijuana facility.


Eligibility criteria:
inclusion criteria: safety cohort * subject was implanted during a breast biopsy procedure with a hydromark breast biopsy site marker manufactured at the devicor tijuana facility per the instructions for use * subject has been followed at least 90 days according to the hospital's standard of care (soc) * subject was ≥ 18 years of age at the time of the breast biopsy procedure * subject has accessible medical records documenting the breast biopsy procedure including, at minimum: age, sex, primary diagnostic indication and documentation of device-related adverse events which occurred, if any performance cohort * subject was implanted during a breast biopsy procedure with a hydromark breast biopsy site marker manufactured at the devicor tijuana facility per the instructions for use * patient is ≥18 years of age * patient has provided informed consent to participate in study, including follow-up visit for ultrasound imaging at 6-12 weeks post-biopsy exclusion criteria: safety cohort • biopsy area was infected at the time of implant performance cohort * contraindication to hydromark breast biopsy site marker implantation * biopsy area is infected at the time of implant * patient has a breast biopsy marker (in the same breast) implanted from a previous procedure

Keywords: radiology breast biopsy ultrasound visibility